$SLS|4Jun 7, 6:36 PM ET

Galena Biopharma, Inc. 4

4 · Galena Biopharma, Inc. · Filed Jun 7, 2016

Form 4

Period: 2016-06-01

Principal Accounting Officer

Transactions

Exercise/Conversion
Common Stock
2016-06-01$1.75/sh+31,250$54,688→ 49,952 total
Exercise/Conversion
Common Stock
2016-06-01$1.85/sh+65,625$121,406→ 115,577 total
Exercise/Conversion
Common Stock
2016-06-01$1.71/sh+30,000$51,300→ 145,577 total
Sale
Common Stock
2016-06-01$2.18/sh−126,875$276,588→ 18,702 total
Exercise/Conversion
Stock Option
2016-06-01−31,250→ 95,625 total
Exercise: $1.75→ Common Stock (31,250 underlying)
Exercise/Conversion
Stock Option
2016-06-01−65,625→ 30,000 total
Exercise: $1.85→ Common Stock (65,625 underlying)
Exercise/Conversion
Stock Option
2016-06-01−30,000→ 0 total
Exercise: $1.71→ Common Stock (30,000 underlying)

Footnotes (5)

[F1]The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.16 to $2.22 per share. The reporting person undertakes the provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The trades settled on June 6, 2016.
[F2]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/15/15).
[F3]This stock option was subject to cancellation on June 29, 2016, which was 90 days after the Reporting person's consulting agreement ended with the Issuer.
[F4]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (7/9/12).
[F5]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/29/13).

Documents

1 file